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Cefotaxime 
Km (μM) kcat  (s-1) kcat/Km  (μM-1s-1) 
 WT 1.32‡ 0.012 0.009 
 N152G 455 1.09 0.002 
 N152S 47 0.56 0.012 
 N152T 800 1.85 0.002 
Cefoxitin 
Km (μM) kcat  (s-1) kcat/Km  (μM-1s-1) 
 WT 0.99‡ 0.11 0.11 
 N152G 56 0.050 0.00090 
 N152S 1.16‡ 0.0083 0.0071 
 N152T 1.12‡ 0.0042 0.0038 
Oxacillin 
Km (μM) kcat  (s-1) kcat/Km  (μM-1s-1) 
 WT 0.053‡ ND* ND* 
 N152G 0.27‡ 0.41 1.52 
 N152S 0.068‡ 0.21 3.17 
 N152T 1.2‡ 1.38 1.15 
β-lactam drugs, such as penicillins and cephalosporins, are widely used to 
treat bacterial infections, but resistance to these drugs is increasingly 
becoming a problem.  One of the main causes of resistance to these β-
lactam drugs is the bacterial production of β-lactamase enzymes, such as 
AmpC.  These enzymes are capable of breaking down the drug within 
their active sites, rendering the antibiotic unable to harm the bacteria.  
The exact roles that the active site amino acid residues play in the 
recognition and breakdown of the drug are not fully understood.  Here, 
we investigate the role of the active site residue asparagine-152 (Asn152) 
in AmpC by mutating it to a glycine, serine, or threonine residue and 
examining the effect that these mutations have on kinetic and structural 
properties.  Uncovering the specific role of Asn152 in the function of 
AmpC will be useful in the development of inhibitors to these enzymes in 
order to combat bacterial resistance.   
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The Michaelis-Menten kinetic constants were determined using UV-Vis 
spectroscopy to follow the hydrolysis of the β-lactam amide bond.  The 
values for the wild type AmpC enzyme and the N152G/S/T mutants with 
3 different β-lactam drugs are shown below.  
Summarizing the kinetics: 
•  Cefotaxime – the mutants are faster than the wild type enzyme, but do 
not bind as well to the drug  
•  Cefoxitin – the N152S and N152T mutants bind the substrate as well as 
the wild type enzyme but are slower to break it down.   
•  Oxacillin – the wild type enzyme does not have measureable activity 
against this drug, but all three mutants show significant activity.  The  
mutants do not all bind oxacillin as well as wild type, but they bind 
oxacillin significantly better than cefoxitin or cefotaxime, producing high 
kcat/Km values. 
The mutations created a substrate specificity switch—allowing the 
enzyme to now break down oxacillin, at the cost of an activity reduction 
against cefoxitin, as well as affinity for cefoxitin and cefotaxime.  
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Figure 1: Proposed mechanism of β-lactam hydrolysis for AmpC 
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Figure 2: Selected amino acids 
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In order to compare the effectiveness of each of the mutants, we 
determined three Michaelis-Menten kinetic constants:   
•  Km – “pseudo”-affinity constant – how well the enzyme binds to the                                  
substrate, a low value indicates tight binding   
•  kcat – the “turnover number” – the total number of products that are 
formed by each enzyme active site per unit of time 
• kcat/Km – overall efficiency – taking binding and rate of turnover into 
account 
 
β-lactam drugs, named for their β-lactam ring, have been used to treat 
bacterial infections for decades; however, bacteria are continually 
becoming resistant to these drugs, creating a growing problem in today’s 
treatment of bacterial infections.  Resistance requires the need for 
stronger, more potent antibiotics and these may not even be able to 
combat the infection. One of the primary mechanisms of resistance to 
these β-lactam drugs is the production of β-lactamases by the bacteria.  
These enzymes are able to hydrolyze the β-lactam ring, turning the drug 
into a molecule that is harmless to the bacteria1. 
One important β-lactamase that is a problem in many pathogens is 
AmpC2. This class C β-lactamase is able to hydrolyze extended-spectrum 
antibiotics, which are usually active against a wide range of bacteria3.  
The proposed mechanism of action of AmpC is shown in figure 1 and 
involves an acyl-intermediate where the substrate is covalently bound to 
the enzyme4.  
 
 
Although the general mechanism is understood, it is unknown how 
specific amino acid residues of the enzyme active site contribute to the 
catalysis, or how they are involved in recognition of the substrate.  
Elucidating the roles of each of the key residues would not only provide 
a clearer picture of the mechanism of hydrolysis of the drugs, but could 
also provide details of substrate recognition and binding for the 
development of new drugs that might combat antibiotic resistance.  
One of the key residues in the active site is asparagine-152. The Asn152 
residue is highly conserved in class C β-lactamases and takes part in the 
active site hydrogen-bonding network5,6. This residue appears to play a 
role in substrate selectivity, as a study done on P99 cephalosporinase, 
another class C β-lactamase, revealed that certain mutations at this site 
led to a switch in substrate selectivity, causing some substrates to be 
hydrolyzed more quickly than the wild type enzyme but others to be 
hydrolyzed more slowly6.  Understanding the exact role of this residue 
could help determine the reason for the substrate specificity of AmpC. 
This information could be used to develop inhibitors that bind very well 
to the active site but are not hydrolyzed (released), thereby inactivating 
the β-lactamase and helping to kill the infectious bacteria. 
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Figure 4: Active site of AmpC N152G in an acyl-intermediate complex with 
cefoxitin.  Blue cages represent electron density contoured at 1σ. Image and 
subsequent images were produced with Pymol 1.3. 
Figure 5: Active site of AmpC N152G in an acyl-intermediate complex with 
cefotaxime.  Blue cages represent electron density contoured at 1σ.  
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Figure 3: β-lactam drugs used in this study, with the β-lactam ring in red, C4 
carboxylate in green, and the amide of the R1 sidechain in blue.  
One other major change between the two structures is the orientation 
of the amide which is on the R1 sidechain, shown in figure 7.  In the 
cefotaxime structure, the carbonyl of the amide points out toward 
residue-152 and hydrogen bonds to a water and Gln120.  In the 
structure of AmpC bound to cephalothin, which a good substrate for 
AmpC, the carbonyl is seen in a similar position and it also hydrogen 
bonds with Asn1527.  Additionally, we see the nitrogen of the amide 
hydrogen bonding with the main chain of Ala318, as is also seen in the 
cephalothin structure.  But in the cefoxitin structure, we find that the 
carbonyl has rotated away from Gln120 and towards Ser64, and it now 
hydrogen bonds with the main-chain nitrogen of Ser64.  The nitrogen 
shows no hydrogen bonds.  This different conformation may be the 
reason behind the slower activity of AmpC against cefoxitin.   
We would like to thank the Office of Undergraduate Research and 
Scholarship at Grand Valley State University for supporting this work. 
Figure 6: Overlay of AmpC N152G acylated to cefoxitin (cyan) or cefotaxime (green), 
focusing on C4 carboxylate.   Red waters and yellow hydrogen bonds are associated 
with the cefoxitin structure, while magenta waters and orange hydrogen bonds are 
associated with the cefotaxime structure. 
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By overlaying the two structures, we can compare the orientations of 
the two drugs. One obvious difference is the orientation of the C4 
carboxylate, shown in figure 6. We see that the C4 carboxylate group on 
the dihydrothiazine ring of the cefotaxime structure hydrogen bonds to 
waters, while the cefoxitin structure shows a flip of the ring and the 
carboxylate now bonds to a water and Gln120. 
Figure 7: Overlay of AmpC N152G acylated to cefoxitin or cefotaxime, focusing on 
the amide of R1 side chain.  Coloring is the same as in figure 6. 
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7. Beadle, B. M., Trehan, I., Focia, P. J. & Shoichet, B. K. (2002). Structure, 10, 413–424. 
In this study, we mutated the Asn152 residue to either a glycine, serine, 
or threonine, shown in figure 2, and examined the effects the mutations 
have on the activity of AmpC from E. coli. 
We measured the ability of the N152 AmpC mutants to break down three 
different β-lactam drugs: cefotaxime, cefoxitin, and oxacillin (figure 3). 
Focusing on the N152G mutant: 
•  It binds cefotaxime and cefoxitin worse than the wild type enzyme.  
•  It is slower to break down cefoxitin than wild type. 
•  It is significantly faster than the wild type enzyme when breaking down   
    cefotaxime.   
To examine the cause of this difference, the structures of AmpC N152G 
acylated to cefoxitin or cefotaxime were determined with X-ray 
crystallography.  The structures of the active site in complex with cefoxitin 
and cefotaxime are shown in figures 4 and 5, respectively.  
• Mutations at residue 152 in AmpC decrease the binding affinity of                 
three different β-lactam drugs 
• These mutations increased the catalytic activity of AmpC against 
cefotaxime and oxacillin and decreased activity against cefoxitin.  
• The crystal structures of AmpC N152G acylated to cefoxitin and 
cefotaxime were used to infer possible reasons behind the different 
rates of hydrolysis of the two drugs, which include rotation of the R1 
amide and flipped dihydrothiazine ring, moving the C4 carboxylate. 
Future work includes determining the structure of AmpC with oxacillin, 
as well as taking additional measurements of kinetic constants in order 
to obtain more precise values.  
β-lactam ring 
amide bond 
inactive 
antibiotic 
 ‡Estimated as Ki    *Not detected 
Table 1: Michaelis-Menten kinetic constants for AmpC  
